These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 15880838)

  • 1. [ApoE genotype and efficacy of neurotrophic and cholinergic therapy in Alzheimer's disease].
    Gavrilova SI; Kolykhalov IV; Korovaĭtseva GI; Zharikov GA; Kalyn IaB; Selezneva ND
    Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(4):27-34. PubMed ID: 15880838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacological approaches to the therapy of Alzheimer's disease].
    Gavrilova SI
    Vestn Ross Akad Med Nauk; 2006; (9-10):30-4. PubMed ID: 17111921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response to rivastigmine transdermal patch or memantine plus rivastigmine patch is affected by apolipoprotein E genotype in Alzheimer patients.
    Han HJ; Kim BC; Lee JY; Ryu SH; Na HR; Yoon SJ; Park HY; Shin JH; Cho SJ; Yi HA; Choi MS; Heo JH; Park KW; Kim KK; Choi SH
    Dement Geriatr Cogn Disord; 2012; 34(3-4):167-73. PubMed ID: 23051684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study.
    Feldman HH; Ferris S; Winblad B; Sfikas N; Mancione L; He Y; Tekin S; Burns A; Cummings J; del Ser T; Inzitari D; Orgogozo JM; Sauer H; Scheltens P; Scarpini E; Herrmann N; Farlow M; Potkin S; Charles HC; Fox NC; Lane R
    Lancet Neurol; 2007 Jun; 6(6):501-12. PubMed ID: 17509485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Neuropsychological evaluation of long-term therapy of Alzheimer's disease using different cerebrolysin dosages].
    Roshchina IF; Gavrilova SI; Zharikov GA; Kalyn IaB; Kolykhalov IV; Selezneva ND
    Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(1):52-5. PubMed ID: 15704485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tacrine and rate of progression in Alzheimer's disease--relation to ApoE allele genotype.
    Sjögren M; Hesse C; Basun H; Köl G; Thostrup H; Kilander L; Marcusson J; Edman A; Wallin A; Karlsson I; Troell M; Wachtmaister G; Ekdahl A; Olofsson H; Sandström A; Andreasen N; Minthon L; Blennow K
    J Neural Transm (Vienna); 2001; 108(4):451-8. PubMed ID: 11475012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The treatment of Alzheimer's disease in patients with comorbid somatic pathology].
    Selezneva ND; Gavrilova SI; Kalyn IaB; Kolykhalov IV; Fedorova IaB
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(7):35-42. PubMed ID: 18833116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term rivastigmine treatment in a routine clinical setting.
    Minthon L; Wallin AK; Eriksson S; Wattmo C; Andreasen N
    Acta Neurol Scand; 2009 Mar; 119(3):180-5. PubMed ID: 18759798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease.
    Karaman Y; Erdoğan F; Köseoğlu E; Turan T; Ersoy AO
    Dement Geriatr Cogn Disord; 2005; 19(1):51-6. PubMed ID: 15383747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical experience with Cerebrolysin.
    Molloy DW; Standish TI
    J Neural Transm Suppl; 2000; 59():293-300. PubMed ID: 10961441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The influence of cerebrolysin on the efficiency of subsequent therapy with amiridine++ in Alzheimer's disease patients (neuropsychological investigation)].
    Roshchina IF; Kolykhalov IV; Selezneva ND; Zharikov GA; Gerasimov NP; Gavrilova SI
    Zh Nevrol Psikhiatr Im S S Korsakova; 1999; 99(12):43-6. PubMed ID: 10629930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained improvements in patients with dementia of Alzheimer's type (DAT) 6 months after termination of Cerebrolysin therapy.
    Rüther E; Ritter R; Apecechea M; Freytag S; Gmeinbauer R; Windisch M
    J Neural Transm (Vienna); 2000; 107(7):815-29. PubMed ID: 11005546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medial temporal lobe atrophy and APOE genotype do not predict cognitive improvement upon treatment with rivastigmine in Alzheimer's disease patients.
    Visser PJ; Scheltens P; Pelgrim E; Verhey FR;
    Dement Geriatr Cogn Disord; 2005; 19(2-3):126-33. PubMed ID: 15627759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease.
    Bullock R; Bergman H; Touchon J; Gambina G; He Y; Nagel J; Lane R
    Curr Med Res Opin; 2006 Mar; 22(3):483-94. PubMed ID: 16574032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Delayed effects of cerebrolysin in the prevention of cognitive impairment progression in the first degree relatives of patients with Alzheimer's disease: the role of the ApoE genotype].
    Selezneva ND; Gavrilova SI; Kolykhalov IV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2020; 120(10. Vyp. 2):31-38. PubMed ID: 33205928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ApoE genotyping and response to galanthamine in Alzheimer's disease--a real life retrospective study.
    Babić T; Mahović Lakusić D; Sertić J; Petrovecki M; Stavljenić-Rukavina A
    Coll Antropol; 2004 Jun; 28(1):199-204. PubMed ID: 15636076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rivastigmine in the treatment of dementia in Alzheimer's disease in adults with Down syndrome.
    Prasher VP; Fung N; Adams C
    Int J Geriatr Psychiatry; 2005 May; 20(5):496-7. PubMed ID: 15852458
    [No Abstract]   [Full Text] [Related]  

  • 18. [The therapeutic potential of cerebrolysin in the preventive therapy of Alzheimer's disease].
    Gavrilova SI; Fedorova IaB; Kolykhalov IV; Odinak MM; Emelin AIu; Kashin AV; Selezneva ND; Kalyn IaB; Roshchina IF
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(8):24-8. PubMed ID: 18833104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease.
    Blesa R; Bullock R; He Y; Bergman H; Gambina G; Meyer J; Rapatz G; Nagel J; Lane R
    Pharmacogenet Genomics; 2006 Nov; 16(11):771-4. PubMed ID: 17047484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential efficacy of treatment with acetylcholinesterase inhibitors in patients with mild and moderate Alzheimer's disease over a 6-month period.
    López-Pousa S; Turon-Estrada A; Garre-Olmo J; Pericot-Nierga I; Lozano-Gallego M; Vilalta-Franch M; Hernández-Ferràndiz M; Morante-Muñoz V; Isern-Vila A; Gelada-Batlle E; Majó-Llopart J
    Dement Geriatr Cogn Disord; 2005; 19(4):189-95. PubMed ID: 15677866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.